Answer · read September 2026
A count of every company reviewed here, and FDA's own dates for what changed.
Most of them. 356 of the 412 telehealth companies reviewed here still list a compounded GLP-1 price (86%), and 66 of those also list a brand drug. 30 sell brand drugs only, with no compounded price at all. FDA ended the shortage-era grace periods in 2025, and in April 2026 it proposed keeping semaglutide, tirzepatide and liraglutide off the list outsourcing facilities compound from.
What this piece found
It declared both shortages over, gave compounders a grace period to wind down shortage-based compounding, and ended it in 2025. In 2026 it turned to marketing and to the list outsourcing facilities compound from. Every line below is FDA's own wording, from pages opened on September 27, 2026.
| Date | What FDA says |
|---|---|
| December 19, 2024 | Today, FDA has issued a new decision determining the tirzepatide injection shortage is resolved.Tirzepatide shortage resolved (re-decided). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| February 18, 2025 | For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from today’s announcement, until February 18, 2025.Tirzepatide: end of the grace period for state-licensed pharmacies (503A). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| February 21, 2025 | FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved.Semaglutide shortage resolved. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| March 19, 2025 | For outsourcing facilities under section 503B, FDA does not intend to take action against compounders for violations of the FD&C Act arising from conditions that depend on tirzepatide injection products’ inclusion on FDA’s drug shortage list until March 19, 2025.Tirzepatide: end of the grace period for outsourcing facilities (503B). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| April 24, 2025 | For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended.Semaglutide: the 503A grace period ends after a court ruling. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 22, 2025 | For outsourcing facilities compounding, distributing or dispensing semaglutide injection products under section 503B, FDA does not intend to take action for violations of the FD&C Act arising from conditions that depend on semaglutide injection products’ inclusion on FDA’s drug shortage list until May 22, 2025.Semaglutide: end of the grace period for outsourcing facilities (503B). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| February 6, 2026 | In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA.FDA says it will restrict GLP-1 ingredients for mass-marketed compounded drugs. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs |
| April 1, 2026 | Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.Neither drug is on the 503B bulks list or the shortage list. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| April 1, 2026 | FDA has stated, at this time, it does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.The four-prescription line for 503A copies. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| April 1, 2026 | For example, FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug productAdding B12 doesn't make it a different drug. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| April 30, 2026 | The U.S. Food and Drug Administration today announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.FDA proposes to keep all three off the 503B bulks list. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List |
None of this made compounding illegal outright. A state-licensed 503A pharmacy can still compound for an individual patient's prescription; what it may not do is regularly compound what FDA calls “essentially a copy” of an approved drug, and FDA counts adding B12 to semaglutide as possibly still a copy. The April 30, 2026 notice is a proposal; FDA's page says it will consider comments before a final determination.
356 of 412. That's every company with a compounded semaglutide, tirzepatide or liraglutide price on its review, read August 2026 to October 2026.
A listed price is what the company advertises, not proof it can fill every order. The compounded semaglutide and compounded tirzepatide pages rank them by what a month costs, and the Price Gap Index tracks the gap between advertised and paid.
Brand drugs: Wegovy, Ozempic, Zepbound, Mounjaro or the pills. 30 companies list brand semaglutide, brand tirzepatide or Foundayo and no compounded drug: Ro, Hims, LifeMD, PlushCare, Push Health, FuturHealth, ZipHealth, Nurx, WeightWatchers, Hers, Allara Health, Sesame, Amazon One Medical, Knownwell, Calibrate, Wellorithm, Layla, AskRx, Better U, Walgreens Weight Management, PrideRx, NovoCare Pharmacy, Wellspring Longevity Clinic, Rex MD, Eve, Hello Alpha, LillyDirect, QuickMD, TeleSlim Clinic and The Virtual NP. The records show what each sells now, not what it sold before, so they can't say which of them once sold a compounded version.
What a brand month costs through them is in brand Zepbound through telehealth, brand Wegovy at Ro, WeightWatchers and LifeMD and the GLP-1 pills online.
26 more fit neither group. 25 price a GLP-1 without naming which molecule it is; 1 list only an oral semaglutide, which on this site covers both the Wegovy pill and compounded oral versions. Does the company name the molecule? covers them.
66 of the 356 compounded sellers, 19%. At those companies the same molecule can come two ways, a compounded plan and the maker's brand drug, at two different prices; the review for each lists both. Two prices on one site covers how that reads on their pages.
No. 46 companies reviewed here have an FDA warning letter on record, and 42 of them still list a compounded price. A warning letter asks a company to correct what FDA found; it isn't an order to stop trading. Is an FDA warning letter a reason to avoid a company? covers what the letters on this roster say.
Three questions, none of them medical:
FDA's statements are quoted from the pages linked in the table above, each opened on September 27, 2026: FDA's running statement on GLP-1 compounding policy (updated April 1, 2026), its February 6, 2026 statement on non-approved GLP-1 drugs and its April 30, 2026 announcement on the 503B bulks list. The company counts are computed from the 412 reviews on this site; each company's own sources are on its review.
Some companies named here pay us a commission when a reader starts care through a marked link. The one marked link on this page is one of them, picked by rule and disclosed beside it. Nothing above is ordered by who pays: the brand-only list runs in roster order, and the counts include every reviewed company. Who pays us · how we review · every review.